Apolipoprotein E and LRP1 Increase Early in Parkinson's Disease Pathogenesis.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  American Journal of Pathology

• Publication date

  2011-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ajpath.2011.07.021PMID 21907175PMCID PMC3204035
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Presence of Tissue Transglutaminase in Granular Endoplasmic Reticulum is Characteristic of Melanized Neurons in Parkinson's Disease Brain

  2011cited by this paper
• Alpha-synuclein, lipids and Parkinson's disease.

  2010cited by this paper
• Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s Disease

  2009cited by this paper
• A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders.

  2009cited by this paper
• Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy

  2009cited by this paper
• Receptor-associated Protein Interacts with Amyloid-β Peptide and Promotes Its Cellular Uptake*

  2009cited by this paper
• Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease

  2008influential reference
• A molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aβ peptides

  2008influential reference
• Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells.

  2007cited by this paper
• Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease.

  2006cited by this paper
• Parkinson's disease: premotor clinico-pathological correlations.

  2006cited by this paper
• Apolipoprotein E Genotype Regulates Amyloid-β Cytotoxicity

  2005cited by this paper
• Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity.

  2005cited by this paper
• LRP and Alzheimer's Disease

  2005cited by this paper
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper
• The roles of receptor-associated protein (RAP) as a molecular chaperone for members of the LDL receptor family.

  2001cited by this paper
• Differential Functions of Triplicated Repeats Suggest Two Independent Roles for the Receptor-associated Protein as a Molecular Chaperone*

  1997cited by this paper
• 39 kDa receptor‐associated protein is an ER resident protein and molecular chaperone for LDL receptor‐related protein.

  1995cited by this paper
• Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

  1993cited by this paper
• Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning.

  1991cited by this paper
• Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease.

  1991cited by this paper
• Apolipoprotein E: cholesterol transport protein with expanding role in cell biology.

  1988cited by this paper

• Assessment of Angiopep-2 targeting intracerebral α-synuclein aggregates in a PFF-induced rat model of Parkinson's disease based on 7T CEST-MRI.

  2026cites this paper
• Astrocytic and microglial cell functions in neuroinflammatory diseases and their animal models

  2025cites this paper
• Multimodal Imaging of Blood–Brain Barrier Dysfunction in Parkinson's Disease: From Pathological Mechanisms to Therapeutic Opportunities

  2025cites this paper
• Increased blood-brain barrier permeability is associated with dysfunctional α band connectivity in early-stage Parkinson’s disease

  2025cites this paper
• A Transcriptomic Roadmap of Parkinson’s Disease Progression at Single Cell Resolution

  2025cites this paper
• LRP1 at the Crossroads of Parkinson's and Alzheimer's: Divergent Roles in α-Synuclein and Amyloid Pathology.

  2025cites this paper
• Uncovering sex differences in Parkinson’s Disease through metaanalysis of single cell transcriptomic studies

  2025cites this paper
• From blood vessels to brain cells: Connecting the circulatory system and Parkinson's disease

  2025cites this paper
• ApoE: The Non-Protagonist Actor in Neurological Diseases

  2024cites this paper
• Role of Lipids in the Pathogenesis of Parkinson’s Disease

  2024cites this paper
• Low-density lipoprotein receptor–related protein 1 mediates α-synuclein transmission from the striatum to the substantia nigra in animal models of Parkinson’s disease

  2024influential citation
• Blood–brain barrier alterations and their impact on Parkinson’s disease pathogenesis and therapy

  2024cites this paper
• Serum Apo Lipoprotein E, Apo Lipoprotein E Gene Polymorphisms, and Parkinson's Disease.

  2024cites this paper
• Osteopontin drives neuroinflammation and cell loss in MAPT-N279K frontotemporal dementia patient neurons.

  2024cites this paper
• Cross interactions between Apolipoprotein E and amyloid proteins in neurodegenerative diseases

  2023cites this paper
• Neuropathology of incidental Lewy body & prodromal Parkinson’s disease

  2023cites this paper
• Microvascular blood-brain barrier alterations in isolated brain capillaries of mice over-expressing alpha-synuclein (Thy1-aSyn line 61).

  2023cites this paper
• Carboxyl truncation of α-synuclein occurs early and is influenced by human APOE genotype in transgenic mouse models of α-synuclein pathogenesis

  2023cites this paper
• Hippocampal synaptic failure is an early event in experimental parkinsonism with subtle cognitive deficit

  2023cites this paper
• Global, in situ analysis of the structural proteome in individuals with Parkinson’s disease to identify a new class of biomarker

  2022cites this paper
• Low levels of soluble low-density lipoprotein receptor-related protein 1 in patients with type 2 diabetes mellitus and diabetic retinopathy.

  2022cites this paper
• Identification of Altered Blood MicroRNAs and Plasma Proteins in a Rat Model of Parkinson’s Disease

  2022cites this paper
• Neuronal ApoE Regulates the Cell-to-Cell Transmission of α-Synuclein

  2022cites this paper
• Soluble LRP-1 in Parkinson’s disease: clues for paradoxical effects

  2022cites this paper
• Endothelial LRP1-ICD Accelerates Cognition-Associated Alpha-Synuclein Pathology and Neurodegeneration through PARP1 Activation in a Mouse Model of Parkinson’s Disease

  2022cites this paper
• Research Evidence of the Role of the Glymphatic System and Its Potential Pharmacological Modulation in Neurodegenerative Diseases

  2022cites this paper
• Identification of RNA markers associated with Parkinson's disease using multiplex gene expression analysis

  2022cites this paper
• Structural and Functional Changes of Reconstituted High-Density Lipoprotein (HDL) by Incorporation of α-synuclein: A Potent Antioxidant and Anti-Glycation Activity of α-synuclein and apoA-I in HDL at High Molar Ratio of α-synuclein

  2021cites this paper
• Basal lamina changes in neurodegenerative disorders

  2021cites this paper
• APOE genotype regulates pathology and disease progression in synucleinopathy

  2020cites this paper
• Understanding the Links Between Cardiovascular Disease and Parkinson's Disease

  2020cites this paper
• Evaluation of α-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinson’s disease and schizophrenia

  2019cites this paper
• Cholesterol Metabolism in the Brain and Its Association with Parkinson’s Disease

  2019cites this paper
• Evaluation of Serum Apolipoprotein E as a Potential Biomarker for Pharmacological Therapeutic Efficacy Monitoring in Dopamine Dictated Disease Spectrum of Schizophrenia and Parkinson’s disease: A Preliminary Study

  2018cites this paper
• Pathophysiology of the Blood–Brain Barrier in Neuroinflammatory Diseases

  2017cites this paper
• Quantitative Electroencephalography and genetics as biomarkers of dementia in Parkinson’s disease

  2017cites this paper
• Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease

  2017cites this paper
• Circulating Cholesterol Levels May Link to the Factors Influencing Parkinson’s Risk

  2017cites this paper
• Differential Expression Profile of Genetic Network for Parkinson's Disease

  2016cites this paper
• Molecular changes in the postmortem parkinsonian brain

  2016cites this paper
• Effects of different isoforms of apoE on aggregation of the α-synuclein protein implicated in Parkinson's disease.

  2016cites this paper
• Cerebrospinal Fluid Peptides as Potential Parkinson Disease Biomarkers: A Staged Pipeline for Discovery and Validation*

  2015cites this paper
• Functional Amyloids in the Mouse Sperm Acrosome

  2014cites this paper
• Alpha synuclein is transported into and out of the brain by the blood-brain barrier.

  2014cites this paper
• Hyperactive glial cells contribute to axonal pathologies in the spinal cord of Npc1 mutant mice

  2014influential citation
• Lipid raft disarrangement as a result of neuropathological progresses: a novel strategy for early diagnosis?

  2013cites this paper
• Plasma Lipoproteins in Brain Inflammatory and Neurodegenerative Diseases

  2012cites this paper